Tags

Type your tag names separated by a space and hit enter

Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.
J Med Virol. 2020 06; 92(6):618-631.JM

Abstract

Recently, a novel coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on toll-like receptor-5 to get binding affinity. Therefore, to provide a fast immunogenic profile of these epitopes, we performed immunoinformatics analysis so that the rapid development of the vaccine might bring this disastrous situation to the end earlier.

Authors+Show Affiliations

Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, Republic of Korea. Department of Zoology, Vidyasagar University, Midnapore, West Bengal, India.Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, Republic of Korea.Department of Zoology, Vidyasagar University, Midnapore, West Bengal, India.Department of Zoology, Vidyasagar University, Midnapore, West Bengal, India.Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea.Department of Zoology, Vidyasagar University, Midnapore, West Bengal, India.Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, Republic of Korea.Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, Republic of Korea. Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32108359

Citation

Bhattacharya, Manojit, et al. "Development of Epitope-based Peptide Vaccine Against Novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics Approach." Journal of Medical Virology, vol. 92, no. 6, 2020, pp. 618-631.
Bhattacharya M, Sharma AR, Patra P, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. J Med Virol. 2020;92(6):618-631.
Bhattacharya, M., Sharma, A. R., Patra, P., Ghosh, P., Sharma, G., Patra, B. C., Lee, S. S., & Chakraborty, C. (2020). Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. Journal of Medical Virology, 92(6), 618-631. https://doi.org/10.1002/jmv.25736
Bhattacharya M, et al. Development of Epitope-based Peptide Vaccine Against Novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics Approach. J Med Virol. 2020;92(6):618-631. PubMed PMID: 32108359.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. AU - Bhattacharya,Manojit, AU - Sharma,Ashish R, AU - Patra,Prasanta, AU - Ghosh,Pratik, AU - Sharma,Garima, AU - Patra,Bidhan C, AU - Lee,Sang-Soo, AU - Chakraborty,Chiranjib, Y1 - 2020/03/05/ PY - 2020/02/22/received PY - 2020/02/26/accepted PY - 2020/2/29/pubmed PY - 2020/7/1/medline PY - 2020/2/29/entrez KW - SARS-COV-2 KW - epitopes KW - immunoinformatics KW - vaccine SP - 618 EP - 631 JF - Journal of medical virology JO - J Med Virol VL - 92 IS - 6 N2 - Recently, a novel coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on toll-like receptor-5 to get binding affinity. Therefore, to provide a fast immunogenic profile of these epitopes, we performed immunoinformatics analysis so that the rapid development of the vaccine might bring this disastrous situation to the end earlier. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32108359/Development_of_epitope_based_peptide_vaccine_against_novel_coronavirus_2019__SARS_COV_2_:_Immunoinformatics_approach_ L2 - https://doi.org/10.1002/jmv.25736 DB - PRIME DP - Unbound Medicine ER -